PRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) ...
Maximize ROI by targeting unmet needs with biomarker-led therapies, differentiated safety and rational combinations, guided by uptake, pricing and market access insights.Dublin, Oct. 06, 2026 (GLOBE ...
Cutaneous T-cell lymphoma, or CTCL, is one of the most stubborn malignancies in hematology and dermatology alike. The disease ...
Among patients with mycosis fungoides (MF) and Sézary syndrome (SS), the T-cell receptor (TCR) clonal Vb20 segment was significantly associated with advanced-stage disease, folliculotropism with ...
CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc ...
HyBryte offers an alternative mechanism of action designed specifically for early-stage CTCL and is positioned to address this unmet need. If approved, HyBryte could become the first available ...
Julia Dai, MD, and Madeleine Duvic, MD, present a comprehensive review of the current state of research and treatment in cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas (CTCLs) are clinically ...
Prescient Therapeutics has entered an important stage in development of its lead cancer drug candidate PTX-100 as Phase 2a data could unlock big pharma partnering opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results